Diabetes Self-Management Blog

This week, we’d like to direct your attention to two blog posts about Exubera, the inhaled insulin product that was approved by the U.S. Food and Drug Administration in 2006 and has not yet been as successful as some analysts had predicted.

The first post, found at www.thediabetesblog.com, critiques manufacturer Pfizer’s plan to begin advertising Exubera directly to patients. This blog entry is written by Allie Beatty, a writer with Type 1 diabetes.

The second post, found at www.diabetesmine.com, reports on recent press treatment of Exubera and the opinions of both industry experts and users on the product’s viability. That blog entry is written by Amy Tenderich, a writer with Type 1 diabetes.

This week, we’d like to direct your attention to two blog posts about Exubera, the inhaled insulin product that was approved by the U.S. Food and Drug Administration in 2006 and has not yet been as successful as some analysts had predicted.

The first post, found at www.thediabetesblog.com, critiques manufacturer Pfizer’s plan to begin advertising Exubera directly to patients. This blog entry is written by Allie Beatty, a writer with Type 1 diabetes.

The second post, found at www.diabetesmine.com, reports on recent press treatment of Exubera and the opinions of both industry experts and users on the product’s viability. That blog entry is written by Amy Tenderich, a writer with Type 1 diabetes.

POST A COMMENT       
  

Comments
  1. There are no comments at this time.


Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


What We're Reading
Take Part in the Big Blue Test! (10/23/14)
Free Webinar on Detecting Health-Care Errors and Fraud (10/17/14)
Ski and Snowboard Camps for Kids With Diabetes (10/06/14)
Project Blue November (10/06/14)

Insulin & Other Injected Drugs
New Weekly Type 2 Diabetes Drug Approved (09/26/14)
Dispelling the Myths of Insulin Therapy (08/01/14)
Insulin for Type 2 (07/14/14)
FDA Approves Inhalable Insulin (07/03/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.